Stryker Repays All Outstanding Debt In Q2, Eyes Ortho/Endoscopic Purchases
This article was originally published in The Gray Sheet
Executive SummaryStryker is readying for acquisitions in the $100 mil.-$200 mil. range now that the company is "virtually debt-free," CEO John Brown stated in a second-quarter earnings call July 15
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.